Hepatitis C Virus Infection in Kidney Transplant Patients: Current Treatment Options

Area of Science:

• Nephrology
• Hepatology
• Transplantation Immunology

Background:

• Hepatitis C virus (HCV) infection is common in kidney transplant recipients, often linked to prior hemodialysis.
• HCV infection is associated with reduced graft and patient survival, liver disease progression, and extrahepatic complications post-transplant.
• Immunosuppressive drugs can accelerate HCV replication after kidney transplantation.

Purpose of the Study:

• To evaluate the efficacy of antiviral treatments for Hepatitis C virus infection in kidney transplant recipients.
• To determine the impact of eradicating HCV on graft and patient survival after kidney transplantation.

Main Methods:

• Review of studies on antiviral treatment options for HCV in kidney transplant recipients.
• Comparison of outcomes between interferon-based therapies and direct-acting antiviral agents (DAAs).

Main Results:

• Interferon-based therapy is associated with a high risk of acute graft rejection in kidney transplant recipients and is rarely used.
• Novel direct-acting antiviral agents (DAAs) have demonstrated high efficacy in treating HCV infection in this patient population.
• Eradication of HCV is crucial for improving graft and patient survival post-transplant.

Conclusions:

• Direct-acting antiviral agents represent a safe and effective treatment for Hepatitis C virus in kidney transplant recipients.
• Antiviral therapy is imperative for enhancing long-term outcomes in kidney transplant recipients with HCV infection.